T2 Biosystems Investor Relations Material

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. The company develops integrated systems for implantable devices and other devices used to administer therapies and monitor outcomes. Its integrated systems provide measurement at the sensor, electronics, and software layers. The company also provides patient adherence monitoring solutions comprising portable medical devices, bio-markers, the Emeter® 2 diabetes management platform, and a new removable stent-based blood glucose meter that captures measurements directly from the body with a minimally invasive procedure called transcutaneous measuring technique (TMT). The company's Transmettor Plus integrates blood glucose data directly into Medtronic's MiniMed® Paradigm insulin pump as well as Dexcom's G4® CGM to improve overall glycemic control. It also offers technology platforms comprising biosensors, electronic circuits, adhesive arrays, and microfluidics for a range of diagnostic applications including potential use in point-of-care (POC) systems. T2 Biosystems is based in Lexington, Massachusetts.